EU Drug Regulatory Network Faces Up To An Uncertain And Complex Future
Tasks To Be Shared By EMA And National Regulators
Executive Summary
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.
You may also be interested in...
EU Stakeholders Want More Focus On Availability Of Medicines
EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.
EU Stakeholders Want More Focus On Availability Of Medicines
EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.
EU Panel Sets Ambitious Big Data Workplan
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.